China Resources 39 has obtained an exclusive license for the innovative brain glioma drug Greater China

ONC201, as a unique mechanism of action developed by Oncoceutics, is currently at a critical clinical stage with oral active small molecule DRD2 antagonists and ClpP astrists.
it has demonstrated its anti-cancer activity and safety in a number of clinical trials, including in adult and child patients with high-level gliomas.
, these trials are known to focus on gliomas containing H3 K27M mutants.
H3 K27M mutated glioma is a subsype of cerebral glioma, defined by molecular parting, with poor clinical prognosis.
recently, the FDA granted ONC201 fast-track eligibility for the treatment of high-level gliomas with relapsed H3 K27M mutations in adults, orphan drug eligibility for the treatment of glioblastomas and H3 K27M mutant gliomas, and identification of rare pediatric diseases for the treatment of H3 K27M mutant gliomas.
resources: .1. Oncoceutics Licenses Rights to ONC201 for Greater China to China Resources Sanjiu Medical and Pharmaceutical Co., Ltd. Retrieved Dec 17, 2020, from Source: Medical Mission Hills